Replies to post #4004 on Repros Therapeutics Inc (RPRX)

[y3maxx]

From today's Business Online...

""Oppenheimer analyst Dr. Brian Abrahams rates Repros outperform with a 12-month target of 19. "Proellex could fill an unmet need in treating fibroids," he says.""

Isn't Oppenheimer is a deal maker?


Rstor...

I'm happy to make fun of myself,,,i'm thick skinned,,,and my reading abilities are just fine,,,but I recognize Dew's statement as conceding for an eventual approval for Proellex,,,subject to any unexpected act of G-d trial result.

,,,As far as diversification goes,,,,I think CAMH is in play currently and for the next Quarter as well.

jmo

good luck